1. Home
  2. SABS vs RWAY Comparison

SABS vs RWAY Comparison

Compare SABS & RWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

SELL

Current Price

$2.95

Market Cap

293.9M

Sector

Health Care

ML Signal

SELL

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

SELL

Current Price

$6.25

Market Cap

274.5M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
SABS
RWAY
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.9M
274.5M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
SABS
RWAY
Price
$2.95
$6.25
Analyst Decision
Strong Buy
Buy
Analyst Count
11
8
Target Price
★ $11.64
$8.18
AVG Volume (30 Days)
★ 624.7K
320.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
★ 21.22%
EPS Growth
★ 78.53
N/A
EPS
N/A
★ 0.08
Revenue
N/A
N/A
Revenue This Year
N/A
$3.03
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$77.94
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$5.19
52 Week High
$5.15
$9.59

Technical Indicators

Market Signals
Indicator
SABS
RWAY
Relative Strength Index (RSI) 45.81 41.38
Support Level $2.44 $5.25
Resistance Level $4.03 $6.77
Average True Range (ATR) 0.21 0.19
MACD -0.01 -0.00
Stochastic Oscillator 18.18 25.79

Price Performance

Historical Comparison
SABS
RWAY

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.

Share on Social Networks: